Thu, Oct 30, 2014, 12:26 PM EDT - U.S. Markets close in 3 hrs 34 mins


% | $
Quotes you view appear here for quick access.

ArQule Inc. Message Board

bladerunner1717 3 posts  |  Last Activity: Oct 21, 2014 1:42 PM Member since: Jan 21, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    tubulsyn phase 1

    by marthastewartstips Oct 17, 2014 8:12 PM
    bladerunner1717 bladerunner1717 Oct 21, 2014 1:42 PM Flag


    What make you so sure that it is the chemotherapeutic warhead and not the (folate) recepetor that is the problem? (I'm going to assume it's not the linker technology, since that technology comes from a leader in field, Seattle genetics.)

  • I don't have the link, but I know it's a fact.

    Sentiment: Strong Buy

  • Cantor Fitzgerald initiated coverage on MEI Pharma (NASDAQ: MEIP) with a Buy rating and a price target of $14.00.

    Analyst Daniel Brims said, "We are initiating coverage of MEIP with a BUY rating and $14 price target, which is based primarily on lead drug candidate Pracinostat’s expected peak revenue of $700M in two indications, MDS and AML. We forecast the commercial launch of Pracinostat in 2017/2018 contributing $10/share to our valuation. MEIP has initiated three Phase 2 trials to assess Pracinostat in front-line AML and MDS, as well as refractory MDS, and we expect several important catalysts for Pracinostat during 4Q:14. Beyond Pracinostat, MEIP is also developing ME-344, which is in Phase 1B testing for small cell lung and ovarian cancer, and PWT-143, a preclinical PI3 Kinase inhibitor. We have assigned $3/share and $1/share in value, respectively, due to the early stage of development of these assets."

    Sentiment: Strong Buy

1.160.00(-0.43%)12:03 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.